Zetomipzomib ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 95 | Autoimmune hepatitis | 1 |
95. Autoimmune hepatitis
Clinical trials : 52 / Drugs : 68 - (DrugBank : 27) / Drug target genes : 18 - Drug target pathways : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05569759 (ClinicalTrials.gov) | January 2023 | 29/9/2022 | A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) | A Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis | Autoimmune Hepatitis | Drug: zetomipzomib;Drug: placebo | Kezar Life Sciences, Inc. | NULL | Recruiting | 18 Years | N/A | All | 24 | Phase 2 | United States |